Observational Study of Survival Outcomes of Stage IV Cancer Patients
Primary Purpose
Stage IV Cancer (Solid Tumors Only), Survival
Status
Unknown status
Phase
Locations
China
Study Type
Observational
Intervention
Sponsored by

About this trial
This is an observational trial for Stage IV Cancer (Solid Tumors Only) focused on measuring Stage IV cancer, Survival
Eligibility Criteria
Inclusion Criteria:
- Presenting with Stage IV cancer (solid tumors only)
Exclusion Criteria:
- Patient declines inclusion
Sites / Locations
- Yang Ling Demonstration Zone Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Arm Label
1. Eligible RCT/Elect RCT
2. Eligible RCT/Elect LDC
3. Eligible RCT/Elect PCO
4. Ineligible RCT/Elect LDC
5. Ineligible RCT/Elect PCO
Arm Description
Eligible for regular chemotherapy, elects and receives regular chemotherapy
Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
Eligible for regular chemotherapy, elects and receives palliative care only
Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
Ineligible for regular chemotherapy, elects and receives palliative care only
Outcomes
Primary Outcome Measures
survival
Secondary Outcome Measures
Full Information
NCT ID
NCT01843985
First Posted
April 27, 2013
Last Updated
April 27, 2013
Sponsor
Cure Cancer Worldwide Corporation
1. Study Identification
Unique Protocol Identification Number
NCT01843985
Brief Title
Observational Study of Survival Outcomes of Stage IV Cancer Patients
Official Title
Observational Study of Survival Times of Stage IV Cancer Patients
Study Type
Observational
2. Study Status
Record Verification Date
April 2013
Overall Recruitment Status
Unknown status
Study Start Date
June 2013 (undefined)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cure Cancer Worldwide Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients diagnosed with Stage IV cancer (solid tumors only) are evaluated to determine whether they are candidates for traditional chemotherapy. If eligible, patients are offered traditional chemotherapy, low-dose chemotherapy, or palliative care. If ineligible, patients are offered low-dose chemotherapy or palliative care. Patients will be monitored for 5 years and survival data recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stage IV Cancer (Solid Tumors Only), Survival
Keywords
Stage IV cancer, Survival
7. Study Design
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1. Eligible RCT/Elect RCT
Arm Description
Eligible for regular chemotherapy, elects and receives regular chemotherapy
Arm Title
2. Eligible RCT/Elect LDC
Arm Description
Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
Arm Title
3. Eligible RCT/Elect PCO
Arm Description
Eligible for regular chemotherapy, elects and receives palliative care only
Arm Title
4. Ineligible RCT/Elect LDC
Arm Description
Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
Arm Title
5. Ineligible RCT/Elect PCO
Arm Description
Ineligible for regular chemotherapy, elects and receives palliative care only
Primary Outcome Measure Information:
Title
survival
Time Frame
months 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Presenting with Stage IV cancer (solid tumors only)
Exclusion Criteria:
Patient declines inclusion
Study Population Description
primary care clinic
Sampling Method
Non-Probability Sample
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
gary smith
Phone
5207492035
Email
garylsmith2@msn.com
Facility Information:
Facility Name
Yang Ling Demonstration Zone Hospital
City
Yang Ling
State/Province
Shaanxi
Country
China
12. IPD Sharing Statement
Learn more about this trial
Observational Study of Survival Outcomes of Stage IV Cancer Patients
We'll reach out to this number within 24 hrs